Deals
QuidelOrtho Weighs Sale of Transfusion Medicine Unit, Sources Say
- Transfusion business could fetch $1.5 billion to $2 billion
- Health-care sector has defied broader dealmaking slump
This article is for subscribers only.
QuidelOrtho Corp. is weighing a sale of its transfusion medicine unit, which could be valued at $1.5 billion to $2 billion, people with knowledge of the matter said.
The San Diego, California-based diagnostics company is working with advisers to gauge potential interest in the unit, according to the people. The business is likely to attract interest from both strategic and private equity suitors, they said.